AlphaStocks
5.0
Consider Buy

Vir Biotechnology, Inc. (VIR)

As of Sep 20, 2026, Vir Biotechnology, Inc. (VIR) scores 5.0/10 on AlphaStocks' five-model composite, #110 of 168 Health Care stocks.

Health Care / Biotechnology

S&P SmallCap 600

$10.60

Below average on several measures. Research carefully.

Consider Buy

Score based on 3 of 5 models — moderate confidence

Data as of Sep 20, 2026

#110out of 168 in Health Care

Is Vir Biotechnology, Inc. a Good Investment in 2026?

Vir Biotechnology, Inc. (VIR) scores 5.0 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model is the most favorable, rating Vir Biotechnology, Inc. as Neutral. However, the Buffett model rates it Caution. Vir Biotechnology, Inc. ranks #110 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-22.4Market Cap2B

Valuation

Currently unprofitable — fair value estimate not available.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

3/9

Buffett

Caution

Business quality & competitive moat

Graham

Neutral

Price vs intrinsic value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is Vir Biotechnology, Inc. (VIR) a good investment?
As of Sep 20, 2026, Vir Biotechnology, Inc. (VIR) scores 5.0/10 on AlphaStocks' five-model composite, #110 of 168 Health Care stocks. That score is below average, suggesting caution. Currently unprofitable — fair value estimate not available.
What is Vir Biotechnology, Inc.'s Piotroski F-Score?
Vir Biotechnology, Inc.'s Piotroski F-Score status is Neutral. The raw score is 3/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is VIR overvalued or undervalued?
A precise fair value estimate is not available for VIR. Currently unprofitable — fair value estimate not available.
How does VIR compare to other Health Care stocks?
Vir Biotechnology, Inc. ranks #110 out of 168 stocks in the Health Care sector, placing it in the top 65% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about VIR?
AlphaStocks evaluates VIR using five proven investment models. Piotroski: Neutral; Buffett: Caution; Graham: Neutral. These models are combined into a single composite score of 5.0/10.

Similar Stocks

ABBVINCYHRMY

Compare VIR with

ABBV vs VIRINCY vs VIRHRMY vs VIRVAL vs VIRPARR vs VIR

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer